(2)
UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 10, 2021(Nasdaq: MRUS) ( Merus , the Company , we , or our ), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced that Merus will present preclinical data from our zenocutuzumab and MCLA-129 programs in three poster presentations at the American Association for Cancer Research 2021 Annual Meeting being held virtually for two weeks, April 10-15, 2021 and May 17-21, 2021.
E-Poster Presentation:
Title: The HER2×HER3 bi-specific antibody zenocutuzumab is effective at blocking growth of tumors driven by NRG1 gene fusions
Abstract #: 956
Session Title: Biological Therapeutic Agents
Title: Zenocutuzumab: An antibody that can overcome HER3 mediated HRG signaling in tumor cells by docking on HER2
Merus N.V.
Merus Announces Presentation of Phase 1 Clinical Data for MCLA-158 at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Symposium
Merus Announces Presentation of Phase 1 Clinical Data for MCLA-158 at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Symposium
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics
® and Triclonics™), today announced that clinical data from its Phase 1 dose escalation study of MCLA-158 will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Symposium (ASCO GI) annual meeting being held virtually from January 15-17, 2021.
Natera to Present New Colorectal Cancer Data at the 2021 ASCO GI Symposium
Oral presentation showcases the largest early-stage CRC cohort to date, further validating the serial use of Signatera™ for early recurrence detection and MRD assessment
News provided by
Share this article
SAN CARLOS, Calif., Jan. 12, 2021 /PRNewswire/
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, at the American Society of Clinical Oncology s 2021 Gastrointestinal Cancers Symposium (ASCO GI), taking place January 15-17, 2021.
Natera will have one oral and one poster presentation, each describing the clinical performance of Signatera in patients with colorectal cancer (CRC).